Sponsored Links
| Quark Announces Dosing Of The First Patient In Phase I Clinical Trial Of Its Ocular Neuroprotective Agent, QPI-1007 |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007. This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION)... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|